| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
|
J Clin Oncol
|
2014
|
6.61
|
|
2
|
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
|
J Clin Oncol
|
2005
|
4.33
|
|
3
|
Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.
|
J Clin Oncol
|
2003
|
3.67
|
|
4
|
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.
|
J Clin Oncol
|
2002
|
3.05
|
|
5
|
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.
|
J Clin Oncol
|
2008
|
2.64
|
|
6
|
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.
|
J Clin Oncol
|
2006
|
2.38
|
|
7
|
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.
|
Clin Cancer Res
|
2009
|
2.02
|
|
8
|
Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504.
|
J Clin Oncol
|
2003
|
1.97
|
|
9
|
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
|
Cancer
|
2008
|
1.73
|
|
10
|
Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).
|
Gynecol Oncol
|
2007
|
1.60
|
|
11
|
Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).
|
J Clin Oncol
|
2003
|
1.58
|
|
12
|
Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model.
|
Am J Clin Pathol
|
2002
|
1.57
|
|
13
|
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.
|
J Clin Oncol
|
2008
|
1.56
|
|
14
|
Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study.
|
Cancer
|
2004
|
1.50
|
|
15
|
Recommendations for collection and handling of specimens from group breast cancer clinical trials.
|
J Clin Oncol
|
2008
|
1.50
|
|
16
|
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.
|
J Clin Oncol
|
2010
|
1.48
|
|
17
|
Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
|
J Urol
|
2007
|
1.42
|
|
18
|
Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
|
J Clin Oncol
|
2005
|
1.33
|
|
19
|
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.
|
J Clin Oncol
|
2007
|
1.32
|
|
20
|
Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial.
|
Gynecol Oncol
|
2005
|
1.31
|
|
21
|
A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience.
|
Br J Haematol
|
2003
|
1.13
|
|
22
|
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
|
J Thorac Oncol
|
2009
|
1.09
|
|
23
|
Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501.
|
J Clin Oncol
|
2003
|
1.06
|
|
24
|
Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI).
|
Br J Haematol
|
2010
|
1.06
|
|
25
|
Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study.
|
Ann Oncol
|
2005
|
0.99
|
|
26
|
Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study.
|
Blood
|
2002
|
0.97
|
|
27
|
Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy.
|
Clin Genitourin Cancer
|
2008
|
0.97
|
|
28
|
The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial.
|
Biol Blood Marrow Transplant
|
2003
|
0.94
|
|
29
|
Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.
|
J Clin Oncol
|
2008
|
0.90
|
|
30
|
A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.
|
Cancer Chemother Pharmacol
|
2005
|
0.89
|
|
31
|
Transoral carbon dioxide laser supraglottic laryngectomy and irradiation in stage I, II, and III squamous cell carcinoma of the supraglottic larynx: report of Southwest Oncology Group Phase 2 Trial S9709.
|
Arch Otolaryngol Head Neck Surg
|
2007
|
0.87
|
|
32
|
Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
|
Gynecol Oncol
|
2005
|
0.84
|
|
33
|
Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.
|
Transplantation
|
2003
|
0.81
|
|
34
|
Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study.
|
Invest New Drugs
|
2006
|
0.81
|
|
35
|
A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study.
|
Cancer
|
2004
|
0.79
|
|
36
|
Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.
|
Clin Cancer Res
|
2001
|
0.79
|
|
37
|
Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer.
|
Invest New Drugs
|
2002
|
0.78
|
|
38
|
Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group clinical trial.
|
Cancer Invest
|
2001
|
0.77
|
|
39
|
Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082.
|
Int J Radiat Oncol Biol Phys
|
2009
|
0.77
|
|
40
|
Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study. Southwest Oncology Group.
|
Invest New Drugs
|
2002
|
0.77
|
|
41
|
Phase II trial of amonafide in central nervous system tumors: a Southwest Oncology Group study.
|
Invest New Drugs
|
2002
|
0.77
|
|
42
|
The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: a Southwest Oncology Group study.
|
Invest New Drugs
|
2002
|
0.76
|
|
43
|
Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220.
|
Ann Thorac Surg
|
2014
|
0.75
|
|
44
|
A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy--Southwest Oncology Group study.
|
Invest New Drugs
|
2002
|
0.75
|
|
45
|
Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group study.
|
Invest New Drugs
|
2002
|
0.75
|
|
46
|
Sequential vinorelbine (V) and docetaxel (D) in advanced non-small cell lung cancer (NSCLC) patients age > 70, or with performance status (PS) 2: A SWOG phase II trial (S0027).
|
J Clin Oncol
|
2004
|
0.75
|
|
47
|
Southwest Oncology Group studies in bladder cancer.
|
Cancer
|
2003
|
0.75
|
|
48
|
Role of T-cell immunity to embryonal stem (ES) cell antigen SOX2 in the progression of myeloma.
|
J Clin Oncol
|
2009
|
0.75
|
|
49
|
The Southwest Oncology Group: progress in cancer research.
|
Semin Oncol
|
2008
|
0.75
|